Establishing laboratory reference ranges for adults and children in Kilifi, Kenya
Preprint
Downs LO. et al, (2024)
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Journal article
Schilling WHK. et al, (2024), PLoS Med, 21
Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trial.
Journal article
Kiguli S. et al, (2024), EClinicalMedicine, 72
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Journal article
Datoo MS. et al, (2024), Lancet, 403, 533 - 544
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)
Preprint
Maitland K. et al, (2024)
A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial).
Journal article
Maitland K. et al, (2024), Wellcome Open Res, 9
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)
Preprint
Maitland K. et al, (2024)
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Journal article
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
[A global core outcome measurement set for snakebite clinical trials].
Conference paper
Abouyannis M. et al, (2023), Med Trop Sante Int, 3
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Journal article
Kimathi D. et al, (2023), Lancet Infect Dis, 23, 974 - 982
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Journal article
Odera DO. et al, (2023), Sci Transl Med, 15
A global core outcome measurement set for snakebite clinical trials.
Journal article
Abouyannis M. et al, (2023), Lancet Glob Health, 11, e296 - e300
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Journal article
Sang S. et al, (2023), Wellcome open research, 8
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Journal article
Hamaluba M. et al, (2023), Wellcome open research, 8
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Journal article
Hamaluba M. et al, (2023), Wellcome Open Res, 8
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART).
Journal article
Maitland K. et al, (2023), Wellcome Open Res, 8
Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial
Journal article
Wamae K. et al, (2022), Wellcome Open Research, 7, 95 - 95
A pragmatic randomized controlled trial of standard care versus steroids plus standard care for treatment of pneumonia in adults admitted to Kenyan hospitals (SONIA)
Journal article
Lucinde R. et al, (2022), Wellcome Open Research, 7, 269 - 269
Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?
Journal article
van der Pluijm RW. et al, (2022), Lancet Infect Dis, 22, 765 - 766